Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

Ildiko Lingvay, Thomas Hansen, Stanislava MacUra, Michel Marre, Michael A. Nauck, Raymond De La Rosa, Vincent Woo, Emre Yildirim, John Wilding

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events'. Together they form a unique fingerprint.

Medicine & Life Sciences